Navigation Links
Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
Date:8/5/2008

ns except for the four endocrine hormones licensed to Schering-Plough.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertaint
'/>"/>

SOURCE Modigene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
2. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
3. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
6. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
7. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
10. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Conn., March 16, 2011 Amarin Corporation plc (Nasdaq: ... on cardiovascular disease, today reported financial results for the ... The Company also provided an update on its progress ... product candidate, AMR101 for the treatment of elevated triglyceride ...
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p098391/Global-Breast-Pumps-Industry.html ... in Thousands of Units by the following Product Segments: ... provides separate comprehensive analytics for the US, Canada, Europe, ...
Cached Medicine Technology:Amarin Reports Year-End and Q4 2010 Results 2Amarin Reports Year-End and Q4 2010 Results 3Amarin Reports Year-End and Q4 2010 Results 4Amarin Reports Year-End and Q4 2010 Results 5Amarin Reports Year-End and Q4 2010 Results 6Amarin Reports Year-End and Q4 2010 Results 7Amarin Reports Year-End and Q4 2010 Results 8Amarin Reports Year-End and Q4 2010 Results 9Global Breast Pumps Industry 2Global Breast Pumps Industry 3Global Breast Pumps Industry 4Global Breast Pumps Industry 5Global Breast Pumps Industry 6Global Breast Pumps Industry 7Global Breast Pumps Industry 8Global Breast Pumps Industry 9Global Breast Pumps Industry 10
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... the potential to ward off depression among retirees, particularly ... online in The Journals of Gerontology, Series ... the article " Internet Use and Depression Among Retired ... ," the authors report that Internet use reduced the ... their study sample. , Late-life depression affects between ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... in heart rate patterns provide information on how the ... long considered heart rate patterns to be important indicators ... as in labor and delivery. Now a new study ... predict the rate at which children develop through their ...
... November 15, 2007, Washington, DCEnsuring that everyone in the ... is not enough to drive the kind of reform ... released today by the Commonwealth Fund Commission on a ... for all, changing the way doctors and other health ...
... doctors for some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay ... whether to allow certain drugs to be sold by ... officials listened to arguments for and against the proposal ... , But at the day,s end, the FDA officials ...
... a favourable clinical outcome in women with ovarian carcinoma, ... research published this week in the online open access ... family of peptide hormones, and the receptor GPR54 have ... tumours. In this study, researchers have shown that kisspeptin ...
... Nov. 14 The following is a,statement from ... Health,(TFAH):, "Trust for America,s Health (TFAH) urges ... Health and Human Services, Education and,Related Agencies Appropriations ... vital programs that:, -- Assist states, territories, ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... For the first quarter of fiscal 2008, the ... the $7,168,160, reported in the prior,year period. This decrease ... and Vascular business units, which decreased 3% and 2%,respectively, ...
Cached Medicine News:Health News:Fetal heart rate yields clues to children's later development 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Predicting the future in ovarian cancer 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... an open platform for clinical diagnostic applications. The ... of 75, 100, 150 and 200 cm ... laboratory space and throughput requirements. Tecan will focus ... new applications and to evolve the quality, safety ...
... For maximum productivity, and proven reliability, ... compact, fully automatic cell washing and ... fast 80-second wash cycle for stat ... controls, and standardized, reproducible procedures. High ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
Medicine Products: